
CLAIMS:

1. A compound of Formula I:




I

or a pharmaceutically acceptable salt, solvate, and/or prodrug thereof,


wherein:

R^1 is selected from H, halo, NH_2, $C_{1\text{-}6}$alkyl, $C_{1\text{-}6}$alkoxy, $NH(C_{1\text{-}6}alkyl)$, and $N(C_{1\text{-}6}alkyl)_2$;


Q is selected from Q1, Q3, Q4, Q5, and Q6:




(Q1),




(Q3),



(Q4),



(Q5), and



(Q6)

 is a single bond or a double bond provided that when in Q1 is a double bond then R^8 and R^{14} are not present, and when in Q6 is a double bond then R^{53} and R^{62} are not present;

R^2 is selected from H, OH, $C_{1\text{-}6}$alkyl, and $C_{1\text{-}6}$alkoxy;

R^5 is selected from H, halo, OH, $C_{1\text{-}6}$alkyl, and $C_{1\text{-}6}$alkoxy;

one or both of R^3 and R^4 is independently selected from H, halo, $C_{1\text{-}6}$alkyl, and $C_{1\text{-}6}$alkoxy, or

R^3 and R^4 are linked together to form $O\text{-}(CH_2)_{1\text{-}2}O$, or

one of R^3 and R^4 is selected from X-L-A and the other of R^3 and R^4 is selected from H, halo, $C_{1\text{-}6}$alkyl, and $C_{1\text{-}6}$alkoxy;

X is selected from O, C(O), NR^a, $NR^aC(O)$, $C(O)NR^a$, OC(O), C(O)O, OC(O)O, $NR^aC(O)O$, $OC(O)NR^a$, and $NR^aC(O)NR^a$;

L is selected from a direct bond, C_{1-6}alkylene, C_{2-6}alkenylene, C_{1-6}alkyleneO, C_{2-6}alkenyleneO, C_{1-6}alkyleneC(O), C_{2-6}alkenyleneC(O), C_{1-6}alkylene$NR^bC(O)$, C_{2-6}alkenylene$NR^bC(O)$, C_{1-6}alkyleneC(O)NR^b, C_{2-6}alkenyleneC(O)NR^b, C_{1-6}alkyleneOC(O), C_{2-6}alkenyleneOC(O), C_{1-6}alkyleneC(O)O, C_{2-6}alkenyleneC(O)O, C_{1-6}alkyleneOC(O)NR^b, C_{2-6}alkenyleneOC(O)NR^b, C_{1-6}alkylene$NR^bC(O)O$, C_{2-6}alkenylene$NR^bC(O)O$, C_{1-6}alkyleneOC(O)O, C_{2-6}alkenyleneOC(O)O, C_{1-6}alkylene$NR^bC(O)NR^b$, and C_{2-6}alkenylene$NR^bC(O)NR^b$;

R^a is selected from H and C_{1-6}alkyl;

R^b is selected from H, C_{1-6}alkyl, and A;

A is selected from H, C_{1-30}alkyl, C_{2-30}alkenyl, phenyl, C_{3-6}cycloalkyl, 3- to 6-membered heterocycloalkyl comprising 1 to 4 heteromoeities independently selected from O, S, S(O), SO_2, N, and NR^{53}, and 5- to 6-membered heteroaryl comprising 1 to 4 heteromoeities independently selected from O, S, S(O), SO_2, N, and NR^{63}, wherein the phenyl, C_{3-10}cycloalkyl, 3- to 6-membered heterocycloalkyl, and 5- to 6-membered heteroaryl are optionally substituted with one or more substituents independently selected from halo, OH, C_{1-4}alkyl, and OC_{1-4}alkyl;

R^7, R^8, R^9, R^{10}, R^{12}, R^{13}, R^{14}, R^{25}, R^{26}, R^{27}, R^{28}, R^{31}, R^{32}, R^{33}, R^{35}, R^{36}, R^{37}, R^{38}, R^{39}, R^{40}, R^{41}, R^{42}, R^{43}, R^{45}, R^{46}, R^{47}, R^{48}, R^{49}, R^{50}, R^{51}, R^{52}, R^{53}, R^{54}, R^{55}, R^{57}, R^{58}, R^{59}, R^{60}, R^{61}, and R^{62} are independently selected from H, halo, and C_{1-6}alkyl;

R^{11}, R^{34}, R^{44}, and R^{56} are independently selected from H, C_{1-6}alkyl, and $C(O)C_{1-6}$alkyl;

R^{29} is C_{1-6}alkyl and R^{30} is selected from H and C_{1-6}alkyl; or

R^{29} is C(O)-A' and R^{30} is selected from H and C_{1-6}alkyl;

wherein A' is selected from Y, O-Y and O-C_{1-4}alkylene-O-C(O)-Y; and

Y is selected from C_{7-30}alkyl and C_{7-30}alkenyl; or

R^{29} and R^{30}, together with the N atom to which they are bound, form a 3- to 6-membered heterocyclic ring which optionally comprises one or two additional heteromoieties independently selected from O, S, S(O), SO_2, N, and NR^{64} and which is optionally substituted with one or more substituents independently selected from halo, OH, C_{1-4}alkyl, and OC_{1-4}alkyl;

R^{63} and R^{64} are independently selected from H and C_{1-6}alkyl; and

all available hydrogen atoms are optionally and independently substituted with a fluorine atom or a chlorine atom and all available atoms are optionally substituted with alternate isotope thereof,

provided when Q is Q3; at least one of R^2, R^3, R^4, R^5, R^{25}, R^{26}, R^{27}, R^{28}, R^{29} and R^{30} is D or comprises D, or at least one of R^2, R^3, R^4, R^5 is alkyl substituted with one or more fluorine and/or chlorine atoms; or at least three of R^2, R^3, R^4, R^5 are not H; or


provided when Q is Q3; R^3 and R^4 are linked together to form O-$(CH_2)_{1-2}$O; or


provided when Q is Q3; one of R^3 and R^4 is selected from X-L-A and the other of R^3 and R^4 is selected from H, halo, C_{1-6}alkyl and C_{1-6}alkoxy; and A is not H, C_{1-6}alkyl or C_{2-6}alkenyl; and

provided when Q is Q1 or Q4 then R^7-R^{14} or R^{31}- R^{40} respectively are not all H, when one of R^3 and R^4 is halo and the other of R^3 and R^4 is H.

2. The compound of claim 1, wherein R^7, R^8, R^9, R^{10}, R^{12}, R^{13}, R^{14}, R^{25}, R^{26}, R^{27}, R^{28}, R^{31}, R^{32}, R^{33}, R^{35}, R^{36}, R^{37}, R^{38}, R^{39}, R^{40}, R^{41}, R^{42}, R^{43}, R^{45}, R^{46}, R^{47}, R^{48}, R^{49}, R^{50}, R^{51}, R^{52}, R^{53}, R^{54}, R^{55}, R^{57}, R^{58}, R^{59}, R^{60}, R^{61}, and R^{62} are independently selected from H and D.

3. The compound of claim 1, wherein Q is selected from one of the following groups:





wherein:

R^{11}, R^{34}, R^{44}, and R^{56} are independently selected from H, D, C_{1-6}alkyl, C_{1-6}fluoroalkyl, C_{1-6}deuteroalkyl, and C(O)-C_1-C_6alkyl; and

R^{29} is selected from C_{1-6}alkyl, C_{1-6}fluoroalkyl, and C_{1-6}deuteroalkyl, and R^{30} is selected from H, D, C_{1-6}alkyl, C_{1-6}fluoroalkyl, and C_{1-6}deuteroalkyl; or

R^{29} is C(O)-A' and R^{30} is selected from H, D, C_{1-6}alkyl, C_{1-6}fluoroalkyl, and C_{1-6}deuteroalkyl.


4. The compound of claim 3, wherein:


R^{11}, R^{30}, R^{34}, R^{44}, and R^{56} are independently selected from H, C_{1-4}alkyl, C_{1-4}fluoroalkyl, and C_{1-4}deuteroalkyl; and


R^{29} is selected from C_{1-4}alkyl, C_{1-4}fluoroalkyl, and C_{1-4}deuteroalkyl.


5. The compound of claim 3, wherein Q is Q3, and wherein R^{29} and R^{30}, together with the N atom to which they are bound, form a 3- to 6-membered heterocyclic ring which comprises one or two additional heteromoieties independently selected from O, N, and NR^{64} and which is optionally substituted with one or more substituents independently selected from halo, OH, C_{1-4}alkyl, and OC_{1-4}alkyl.

6. The compound of claim 3, wherein Q is selected from one of the following groups:



,


,


and


,

wherein R^{34} is selected from H, D, C_{1-6}alkyl, C_{1-6}fluoroalkyl, C_{1-6}deuteroalkyl, and C(O)-A'.

7. The compound of claim 1 or claim 3, wherein Q is Q3, wherein R^{29} is C(O)-A' and R^{30} is selected from H and C_{1-6}alkyl.

8. The compound of any one of claims 1 to 7, wherein R^1 is selected from H, halo, NH_2, C_{1-4}alkyl, C_{1-4}alkoxy, $NH(C_{1-4}alkyl)$, and $N(C_{1-4}alkyl)_2$.

9. The compound of any one of claims 1 to 8, wherein R^2 is selected from H, D, OH, C_{1-4}alkyl, C_{1-4}alkoxy, C_{1-4}fluoroalkyl, C_{1-4}deuteroalkyl, C_{1-4}deuteroalkoxy, and C_{1-4}fluoroalkoxy, and R^5 is selected from H, D, Cl, F, OH, C_{1-4}alkyl, C_{1-4}alkoxy, C_{1-4}fluoroalkyl, C_{1-4}deuteroalkyl, C_{1-4}deuteroalkoxy, and C_{1-4}fluoroalkoxy.

10. The compound of any one of claims 1 to 9, wherein one or both of R^3 and R^4 is independently selected from H, D, F, Cl, C_{1-6}alkyl, C_{1-6}fluoroalkyl, C_{1-6}deuteroalkyl, C_{1-6}alkoxy, C_{1-6}fluoroalkoxy, and C_{1-6}deuteroalkoxy.

11. The compound of any one of claims 1 to 9, wherein R^3 and R^4 are linked together to form O-CH_2O.

12. The compound of any one of claims 1 to 9, wherein one of R^3 and R^4 is selected from X-L-A and the other of R^3 and R^4 is selected from H, halo, C_{1-6}alkyl, and C_{1-6}alkoxy.

13. The compound of claim 12, wherein R^3 is selected from H, halo, C_{1-6}alkyl, and C_{1-6}alkoxy, and R^4 is X-L-A.

14. The compound of claim 1, wherein:

R^1 is H;

R^2 is selected from H and D;

R^5 is selected from H, D, and F;


one or both of R^3 and R^4 is selected from H, C_{1-4}alkoxy, C_{1-4}fluoroalkoxy, and C_{1-4}deuteroalkoxy, or









R^3 and R^4 are linked together to form O-$(CH_2)_{1-2}$O;








R^7, R^8, R^9, R^{10}, R^{12}, R^{13}, R^{14}, R^{25}, R^{26}, R^{27}, R^{28}, R^{31}, R^{32}, R^{33}, R^{35}, R^{36}, R^{37}, R^{38}, R^{39}, R^{40}, R^{41}, R^{42}, R^{43}, R^{45}, R^{46}, R^{47}, R^{48}, R^{49}, R^{50}, R^{51}, and R^{52} are independently selected from H and D; and










R^{11}, R^{30}, R^{34}, and R^{44} are independently selected from H, C_{1-4}alkyl, C_{1-4}fluoroalkyl, and C_{1-4}deuteroalkyl; andR^{29} is selected from C_{1-4}alkyl, C_{1-4}fluoroalkyl, and C_{1-4}deuteroalkyl.








15. The compound of claim 1 selected from:









Compound ID	Structure
I-1	









I-2	
I-3	
I-4	
I-5	
I-6	
I-7	
I-8	
I-9	









I-24	
I-25	
I-26	
I-27	
I-28	
I-29	
I-30	









(R)-I-31	
I-32	
I-33	
I-34	
I-35	
I-36	
I-37	
I-38	
I-39	









I-40	
I-41	
I-42	
I-43	
I-44	
I-45	
I-46	









(R)-I-47	
(R)-I-48	
(R)-I-49	
(R)-I-50	
(R)-I-51	
(R)-I-52	
(S)-I-53	
(R)-I-53	








(R)-I-54	
(R)-I-55	
(R)-I-56	
(R)-I-57	
(S)-I-57	
(R)-I-58	
(R)-I-59	
(R)-I-60	






(R)-I-61	
(R)-I-62	
(R)-I-63	
(R)-I-74	
(R)-I-77	
(R)-I-78	
(R)-I-79	
(R)-I-80	




(R)-I-81	
(R)-I-82	
(R)-I-83	
(R)-I-84	
(R)-I-85	
(R)-I-86	
(R)-I-87	
(R)-I-88	

(R)-I-89	
(R)-I-90	
(R)-I-91	
(R)-I-92	
(R)-I-93	
(R)-I-94	
(R)-I-95	
(R)-I-96	

(R)-I-97	
(R)-I-98	
(R)-I-99	
(R)-I-100	
(R)-I-101	
(R)-I-102	
(R)-I-103	
(R)-I-104	

I-105	
I-106	
I-107	
I-108	
I-110	
(R)-I-111	
(S)-I-111	

(R)-I-112	
I-113	
I-114	
(S)-I-115	
(S)-I-116	

I-119	
(R)-I-120.HCl	 .HCl, and
(R)-I-121.HCl	 .HCl

or a pharmaceutically acceptable salt, solvate, and/or prodrug thereof.

16. A composition comprising one or more compounds of any one of claims 1 to 15 and a carrier.

17. Use of one or more compounds of any one of claims 1 to 15, the composition of claim 16 or the pharmaceutical composition of claim 20 in the manufacture of a medicament for treating a mental illness.

18. Use of one or more compounds of any one of claims 1 to 15, the composition of claim 16 or the pharmaceutical composition of claim 20 in the manufacture of a medicament for treating a CNS disease, disorder, or condition and/or a neurological disease, disorder, or condition.

19. Use of one or more compounds of any one of claims 1 to 15, the composition of claim 16 or the pharmaceutical composition of claim 20 in the manufacture of a medicament for treating a mental disease or a behavioral problem.

20. A pharmaceutical composition comprising a compound of any one of claims 1 to 15 and an additional therapeutic agent.

21. One or more compounds of any one of claims 1 to 15, the composition of claim 16 or the pharmaceutical composition of claim 20 for use in therapy.